Skip to main content
Log in

Susceptibility of clinical isolates of yeasts to anti-fungal agents

  • Published:
Mycopathologia Aims and scope Submit manuscript

Abstract

The antimicrobial activity of amphotericin B, 5-fluorocytosine, nystatin, clotrimazole and miconazole were compared in vitro against 244 strains of yeasts that had been isolated from clinical specimens. The yeasts used in this study included 20 species of Candida, Cryptococcus, Saccharomyces Geotrichum, Rhodotorula, Torulopsis and Trichosporon. The majority of the strains (78%) had an MIC of ≤0.5 μg/ml for amphotericin B, 81% an MIC of ≤1 μg/ml for 5-fluorocytosine, 99% ≤8 μg/ml for nystatin, 91%, ≤8.0 μg/ml for clotrimazole and 98% had an MIC of ≤4.0 for miconazole. Of the anti-fungal agents tested, 5-fluorocytosine and nystatin were found to have the greatest antifungal activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Adams ED, Jr, Cooper BHA: Evaluation of a modified Wickerham medium for identifying medically important yeasts. Am J Med Technol 40:377–388, 1974.

    Google Scholar 

  2. Bodey GP, Rodriguez V: Infections in cancer patients on a protected environment-prophylactic antibiotic program. Am J Med 59:97–504, 1975.

    Google Scholar 

  3. Bergan T, Vangdal M: In vitro activity of antifungal agents against yeasts species. Chemotherapy 29:104–110, 1983.

    Google Scholar 

  4. Clayton YM: Therapy of fungal infections. Br J Derm 89:423–425, 1973.

    Google Scholar 

  5. Cooper BH, Silva-Hunter M: Medically important yeasts. In Lennette EH, Balows A, Hausler WJ, Jr, Shadomy HJ (eds) Manual of clinical microbiology, 4th ed, Washington, DC, Am Soc Microbiol, 1985, 526–541.

    Google Scholar 

  6. Dick JD, Rosengard BR, Merz WG, Stuart RK, Hutchins GM, Saral R: Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii. Ann Intern Med 102:67–68, 1985.

    Google Scholar 

  7. Ghannoum MA, Sharif HF, Al-Gharear H: Sensitivity of clinical isolates in Kuwnit against a number of antifungal agents. Mykosen 27:402–410, 1983.

    Google Scholar 

  8. Guinet R, Chanas J, Goullier A, Bonnefoy G, Ambroise-Thomas P: Fatal septecemia due to amphotericin-Bresistant Candida lusitaniae. J Clin Microbiol 18:443–444, 1983.

    Google Scholar 

  9. Hamilton-Miller JMT: A comparative in vitro study of amphotericin B, clotrimazole and 5-fluorocytosine against clinically isolated yeasts. Sabouraudia 10:276–283, 1972.

    Google Scholar 

  10. Hamilton-Miller JMT: Fungal sterols and the mode of action of the polyene antibiotics. Adv Appl Microbiol 17:109–134, 1974.

    Google Scholar 

  11. Hart PD, Russell EB, Jr, Remington JS: The compromised host and infection. II. Deep fungal infection. J Infect Dis 120:169–191, 1969.

    Google Scholar 

  12. Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS: Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections. Drugs 19:7–30, 1980.

    Google Scholar 

  13. Hersh EM, Bodey GP, Niles GA, Freireich EJ: Causes of death in acute leukemia. A ten-year study of 414 patients from 1954–1963. J Am Med Assoc 193:99–103, 1965.

    Google Scholar 

  14. Klainer AS, Beisel WR: Opportunistic infection: a review. Am J Med Sci 258:431–456, 1969.

    Google Scholar 

  15. Littman ML, Pisano MA, Lancaster RM: Induced resistance to Candida species to nystatin and amphotericin B. Antibiotics Annual 1957–1958:981–987, 1958.

  16. McGowan JE, Jr, Barnes MW, Finland M: Bacteremia at Boston City Hospital. Occurrence and mortality during 12 selected years (1935–1972), with special reference to hospital acquired cases. J Infect Dis 132:316–335, 1975.

    Google Scholar 

  17. Mennier-Carpentier F, Kiehn TE, Armstrong D: Fungemia in the immunocompromised host. Am J Med 71:363–370, 1981.

    Google Scholar 

  18. Pappagianis HD, Collins MS, Hector R, Remington J: Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob Agents Chemother 16:123–126, 1979.

    Google Scholar 

  19. Shadomy S: Further in vitro studies with 5-fluorocytosine. Infect Immunity 2:484–488, 1970.

    Google Scholar 

  20. Shadomy S, Espinel-Ingroff A, Cartwright R: Laboratory studies with antifungal agents: susceptibility tests and bioassays. In Lennette EH, Balows A, Hausler WJ, Jr, Shadomy HJ (eds) Manual of clinical microbiology, 4th ed, Washington, DC, Am Soc Microbiol, 1985, 991–999.

    Google Scholar 

  21. Stone HH, Kolb LD, Currie CA, Geheber CE, Cuzzell JZ: Candid sepsis: pathogenesis and principles of treatment. Ann Surg 179:697–710, 1974.

    Google Scholar 

  22. Wickerham LJ, Burton KA: Carbon assimilation tests for the classification of yeasts. J Bact 56:363–371, 1984.

    Google Scholar 

  23. Woods RA, Bard M, Jackson IE, Drutz DJ: Resistance to polyene antibiotics and correlated sterol changes in two isolates of Candida tropicalis from a patient with an amphotericin B resistant funguria. J Infect Dis 129:53–58, 1974.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hussain Qadri, S.M.H., Flournoy, D.J., Qadri, S.G.M. et al. Susceptibility of clinical isolates of yeasts to anti-fungal agents. Mycopathologia 95, 183–187 (1986). https://doi.org/10.1007/BF00437125

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00437125

Keywords

Navigation